Registration and Breakfast

UKTI – Fast track to the world
Harriet Fear, Team Leader Life sciences sector team, UK Trade & Investment

San Diego

The roots of innovation: San Diego’s Life Science Industry

• Mr Joseph Panetta, CEO
  BIOCOM

Watching the Detectives

The changing role of sensors and biomarkers in the bio-pharma, devices and diagnostics industries

Sensors are much more than simply a reliable method of detecting antibodies in blood,whilst biomarkers are playing an increasingly important role in applications ranging from stem cell biology, to genetics and genotyping. Experts from Cambridge explain how their sensors are changing not just the way we diagnose and monitor disease, but the role of sensors in the investigation of novel therapeutic agents. In this session we also hear how bio-pharma companies are using advances in biomarker discovery as effective tools in pre-clinical studies as well as clinical trials.

This session is introduced by Professor Chris Lowe, Director, Institute of Biotechnology, University of Cambridge, co-founder of multiple biosensor companies.

Chairing the session: Professor Chris Lowe, Founder, Smart Holograms Ltd

• Dr Matthew Cooper, Chief Scientist
  Akubio Ltd
• Dr Duncan Purvis, Technical and Business Development Director
  Universal Sensors Ltd
• Mr Phil Teale,Chief Scientist
  HFL
• Dr Brian Burke, South UK Territory Manager
  Cogenics

Morning Break

The Known Unknowns of Funding Drug Discovery

The future of drug discovery is dogged with uncertainty, especially when it comes to raising finance. Is it worth trying to predict the market’s next move, or are you simply at the mercy of market forces?

In this session we examine the pros and cons of financing drug discovery through licensing deals versus raising private or public finance. We hear from companies that have demonstrated nimble-footed efficiency in their fund raising strategies, and learn how they have adapted to changes in the market.

Chairing the session:Dr Jonathan Lewis, Director Business Development, Genentech

• Dr Derek Jones, Director
  Vastox Plc

• Dr Roland Kozlowski, CEO
  Lectus Therapeutics Ltd
• Mr John Aston, CFO
  Astex Therapeutics Ltd
• Mr Nick Higgins, CEO
  Intercytex  

Networking Lunch

The Future’s Here

From “cells in wells” to growing cells without “shaking, stirring, rocking or rolling”; fromself-healing body parts to simultaneous genome sequencing in this session we hear from companies for whom the future’s not just bright, but happening right here, right now.

The conference will also hear from the CEO’s of tomorrow – Student Entrepreneurs.

Supported by

Chairing the session:

Dr John Shields, Principal, Science and Technology, Abingworth Management Ltd

• Dr Kevin Auton, CEO
  Cellexus
• Ms Julie Kerby, Business Unit Manager
  Stem Cell Sciences UK Ltd
• Prof Conrad Lichtenstein, COO
  Population Genetics Technologies Ltd
• Dr Andrew Lynn, CEO
  OrthoMimetics
• Dr Julian Gilbert, CEO
  Acacia Pharma
• Dr Ramin Pirzad

VapTEC

• Dr Berwyn Clarke, CSO

Lab21 Ltd

Drinks Reception in the James Watson Room